Acquired by Xeris Pharmaceuticals in October 2021
SBBP - Strongbridge Biopharma plc
NASDAQ
->
Healthcare
->
Biotechnology
Trevose,
United States
Type: Equity
SBBP price evolution
SBBP
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $63.77 | $73.9 | $87.52 | $81.79 |
| Short term investments | ||||
| Net receivables | $3.58 | $2.85 | $2.8 | $2.9 |
| Inventory | $1.1 | $1.01 | $1.1 | $1.12 |
| Total current assets | $70.12 | $79.66 | $92.35 | $87.36 |
| Long term investments | ||||
| Property, plant & equipment | $0.67 | $0.75 | $0.81 | $0.88 |
| Goodwill & intangible assets | $24.83 | $26.09 | $27.34 | $28.6 |
| Total noncurrent assets | $26.7 | $28.39 | $28.75 | $30.29 |
| Total investments | ||||
| Total assets | $96.82 | $108.05 | $121.1 | $117.65 |
| Current liabilities | ||||
| Accounts payable | $0.64 | $5.74 | $1.48 | $1.59 |
| Deferred revenue | ||||
| Short long term debt | $0.71 | |||
| Total current liabilities | $23.38 | $21.98 | $21.13 | $19.36 |
| Long term debt | $17 | $17.4 | $17.11 | $7.27 |
| Total noncurrent liabilities | $29.05 | $30.23 | $34.36 | $23.72 |
| Total debt | $17.71 | $17.4 | $17.11 | $7.27 |
| Total liabilities | $52.43 | $52.2 | $55.49 | $43.08 |
| Shareholders' equity | ||||
| Retained earnings | -$330.61 | -$317.37 | -$305.56 | -$293.61 |
| Other shareholder equity | $0.04 | $0.04 | $0.04 | |
| Total shareholder equity | $44.39 | $55.85 | $65.61 | $74.57 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $87.52 | $57.03 | $122.49 | $57.51 |
| Short term investments | $21.07 | |||
| Net receivables | $2.8 | $2.29 | $1.63 | $1.58 |
| Inventory | $1.1 | $1.99 | $3.95 | $0.51 |
| Total current assets | $92.35 | $83.54 | $132.3 | $60.81 |
| Long term investments | ||||
| Property, plant & equipment | $0.81 | $1.08 | $0.29 | $0.01 |
| Goodwill & intangible assets | $27.34 | $32.37 | $37.39 | $42.41 |
| Total noncurrent assets | $28.75 | $34.09 | $37.99 | $43.11 |
| Total investments | $21.07 | |||
| Total assets | $121.1 | $117.64 | $170.28 | $103.92 |
| Current liabilities | ||||
| Accounts payable | $1.48 | $3.33 | $1.18 | $1.25 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $21.13 | $24.29 | $17.25 | $12.48 |
| Long term debt | $17.11 | $37.79 | ||
| Total noncurrent liabilities | $34.36 | $21.15 | $40.08 | $103.36 |
| Total debt | $17.11 | $37.79 | ||
| Total liabilities | $55.49 | $45.45 | $57.33 | $115.84 |
| Shareholders' equity | ||||
| Retained earnings | -$305.56 | -$260.48 | -$211.03 | -$242.88 |
| Other shareholder equity | $0.04 | $0 | $0.04 | $0.04 |
| Total shareholder equity | $65.61 | $72.19 | $112.95 | -$11.91 |
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.04 | $8.38 | $8.23 | $8.07 |
| Cost of revenue | $0.47 | $0.41 | $0.44 | $0.41 |
| Gross Profit | $9.57 | $7.97 | $7.78 | $7.66 |
| Operating activities | ||||
| Research & development | $5.4 | $5.84 | $5.32 | $6.77 |
| Selling, general & administrative | $15.99 | $10.95 | $11.61 | $9.22 |
| Total operating expenses | $22.68 | $18.04 | $18.18 | $17.25 |
| Operating income | -$13.11 | -$10.07 | -$10.4 | -$9.58 |
| Income from continuing operations | ||||
| EBIT | -$12.43 | -$11.03 | -$11.4 | -$2.64 |
| Income tax expense | $0 | -$0.01 | ||
| Interest expense | $0.81 | $0.78 | $0.56 | $0.52 |
| Net income | ||||
| Net income | -$13.24 | -$11.81 | -$11.95 | -$3.16 |
| Income (for common shares) | -$13.24 | -$11.81 | -$11.95 | -$3.16 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $30.73 | $21.71 | $18.03 | $7.05 |
| Cost of revenue | $2.21 | $3.82 | $3.99 | $1.48 |
| Gross Profit | $28.52 | $17.89 | $14.04 | $5.56 |
| Operating activities | ||||
| Research & development | $25.8 | $30.9 | $25.44 | $17.27 |
| Selling, general & administrative | $40.87 | $49.06 | $63.34 | $36.29 |
| Total operating expenses | $71.68 | $84.98 | $95.96 | $79.31 |
| Operating income | -$43.16 | -$67.09 | -$81.92 | -$73.74 |
| Income from continuing operations | ||||
| EBIT | -$43.75 | -$47.68 | $44.9 | -$107.4 |
| Income tax expense | -$0.01 | $1.77 | $0.54 | $1.77 |
| Interest expense | $1.34 | $12.52 | $4.31 | |
| Net income | ||||
| Net income | -$45.08 | -$49.45 | $31.85 | -$113.48 |
| Income (for common shares) | -$45.08 | -$49.45 | $31.85 | -$113.48 |
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Net income | -$13.24 | -$11.81 | -$11.95 | -$3.16 |
| Operating activities | ||||
| Depreciation | $1.28 | $1.28 | $1.28 | $1.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.08 | $2.28 | $1.79 | $2.07 |
| Total cash flows from operations | -$9.83 | -$13.39 | -$5 | -$5.76 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | ||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | $21.11 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.18 | $0.73 | $27.87 | |
| Net borrowings | $10 | -$0.14 | ||
| Total cash flows from financing | -$0.3 | -$0.22 | $10.73 | $27.65 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.12 | -$13.62 | $5.73 | $21.88 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$45.08 | -$49.45 | $31.85 | -$113.48 |
| Operating activities | ||||
| Depreciation | $5.11 | $5.1 | $7.23 | $5.03 |
| Business acquisitions & disposals | $134.66 | -$7.5 | ||
| Stock-based compensation | $7.38 | $8.6 | $7.81 | $5.17 |
| Total cash flows from operations | -$38.13 | -$44.78 | -$84.58 | -$45.34 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.07 | -$0.33 | |
| Investments | $21.12 | -$20.69 | ||
| Total cash flows from investing | $21.11 | -$20.76 | $134.33 | -$7.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $28.6 | $0.18 | $65.76 | $27.08 |
| Net borrowings | $19.32 | -$50.06 | $16.43 | |
| Total cash flows from financing | $47.51 | $0.09 | $15.23 | $43.51 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $30.49 | -$65.46 | $64.98 | -$9.33 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 67.83M |
| Revenue | $34.72M |
|---|---|
| EBITDA | -$32.39M |
| EBIT | -$37.50M |
| Net Income | -$40.16M |
| Revenue Q/Q | 29.41% |
| Revenue Y/Y | 34.98% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.65 |
| Cash/Share | 0.94 |
| EPS | -$0.59 |
|---|---|
| ROA | -36.21% |
| ROE | -66.82% |
| Debt/Equity | 0.85 |
|---|---|
| Net debt/EBITDA | 0.35 |
| Current ratio | 3.00 |
| Quick ratio | 2.95 |